Device/Drug Borderline: Gray Areas Remain Despite New EU Guidance
Executive Summary
The regulation of products on the drug/device borderline has always been complex. New EU guidance aims to provide clarification, but some difficult and nuanced decision-making is still left to the manufacturer.
You may also be interested in...
EU’s Risk Management Standard Officially Recognized In Context Of The IVDR
Only one new standard has been added to the official list of standards recognized in the context of the EU IVD Regulation in the latest update. The good news is that it is arguably one of the most needed standards by the IVD industry after the medtech quality management standard, ISO 13485.
EU Notified Bodies Told To Comply With Russia/Belarus Sanctions
Given the ongoing conflict in Ukraine, EU medtech notified bodies have been told to comply with sanctions intended to hurt companies based in Russia and Belarus.
Hot Topics On The EU’s Immediate Regulatory Agenda: Six Documents To Endorse
Vital MDR and IVDR implementation documents and measures are listed for endorsement at the forthcoming meeting of the European Commission’s Medical Device Coordination Group.